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ABSTRACT
Venous thromboembolism (VTE) affects 0.1–0.3% people each year. The risk of VTE following gynecological surgery and 
invasive procedures is well established and presents one of the major challenges in gynecological practice. Moreover, 
commonly use assisted reproductive techniques (ART) are reported to increase the risk of VTE. Despite continued efforts 
to reduce its incidence, postoperative VTE remains the second most common perioperative complication and the third 
most common cause of mortality. 
Several practice guidelines have been developed regarding prophylaxis and treatment of VTE. However, there is a large 
inconsistency between the recommendations and the medical practice in various centers. Moreover, prophylaxis in gy-
necological patients and women undergoing ART should be chosen individually for the patient, taking into account the 
possible risk factors for VTE and perioperative bleeding complications. Until recently, the percentage of women, who have 
not received anticoagulant prophylaxis or administrated it inadequately may reach 50%. 
This paper presents the current recommendations regarding thromboprophylaxis in women undergoing gynecological 
surgery or assisted reproductive techniques and addresses challenging practical issues in this field.
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INTRODUCTION
Venous thromboembolism (VTE), i.e. deep vein throm-
bosis (DVT) and pulmonary embolism (PE), affect 1 to 3 per 
1000 persons per year [1]. It is estimated that in Poland DVT 
is diagnosed in approximately 50,000 people per year, while 
20,000 patients per year suffer from PE [1]. Pulmonary em-
bolism leads to death in 30% of the patients, while a proper 
anticoagulation therapy reduces PE-related mortality to 
2–8% [2, 3]. 
Surgery and invasive procedures are the well estab-
lished risk factors of VTE. Despite continued efforts to reduce 
its incidence, postoperative VTE remains the second most 
common perioperative complication and the third most 
common cause of mortality [4]. The risk of VTE depends on 
genetic and environmental factors such as age, sex, throm-
bophilia, history of VTE, malignancy or hormone therapy, all 
these risk factors may additionally increase the VTE risk in 
perioperative period [5]. 
Surgical gynecological patients are at a particularly 
high risk of developing VTE [6]. Although several practice 
guidelines have been developed regarding prophylaxis and 
treatment of VTE, there is a large inconsistency between 
the recommendations and the medical practice in various 
centers. Even though many strategies have been proposed 
to improve the effectiveness and safety of VTE prophylaxis 
and treatment, it remains unsatisfactory [7].
Moreover, recommendations of VTE prophylaxis issued 
by the Polish Gynecological Society differ from guidelines 
recommended by other societies [8].
Therefore, this review article presents the current rec-
ommendations regarding thromboprophylaxis in women 
undergoing gynecological surgery or assisted reproductive 
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techniques and addresses challenging practical issues in 
this field. 
THROMBOPROPHYLAXIS IN GYNECOLOGY 
The prevalence of VTE after gynecologic surgery var-
ies from 15% to 30% depending on the approach used 
for diagnosis, and fatal PE occurs in 0.2–0.9% of patients 
[9, 10]. Several independent risk factors for VTE were iden-
tified in a gynecological population, including a history of 
VTE, current diagnosis of gynecologic cancer, increasing 
age, African American race and prolonged surgical time. 
The risk of VTE after gynecologic laparoscopic surgery is 
uncertain. When prescribing antithrombotic prophylaxis 
before gynecological surgery, additional VTE risk factors 
must be taken into account such as the extent and dura-
tion of the surgery, surgical technique, and type of surgery 
(hysterectomy, myomectomy) and anesthesia. All women 
scheduled for gynecological surgery should be assessed 
in terms of the VTE risk and eligibility to thromboprophy-
laxis using a validated scoring system and recommended 
in a given hospital.
The American College of Chest Physicians (ACCP) guide-
lines incorporated a risk stratification model, the Caprini risk 
assessment model, in which each independent risk factor is 
associated with specific points (range from 1 to 5) based on 
the risk for VTE for each factor (Table 1) [10].
Mechanical prophylactic measures
Since postoperative thrombi mostly begin within 
24 hours after the surgery in the capacitance calf vein. Re-
duction in DVT formation with this method was observed 
in 36% women, although graduated compression stockings 
were more effective when combined with an additional 
prophylactic method in women undergoing pharmacologi-
cal measures [11]. Venous stasis reduction is achieved by 
regularly compression of calf with tight. When used during 
and after major gynecologic surgery Intermittent pneumatic 
compression (IPS) appear to be as effective as low-dose 
unfractionated heparin (UFH) and low molecular weight 
heparin (LMWH) in reducing DVT incidence up to 69% [11]. 
However, this type of thromboprophylaxis is infrequently 
used in Polish hospitals.
Low-dose unfractionated heparin (UFH)
When administered subcutaneously starting 2 hours 
before surgery and continued every 8–12 hours postop-
eratively, numerous controlled trials have found low-dose 
unfractionated heparin effective in preventing VTE. A major 
concern is the potential for increased perioperative bleeding 
complications. Moreover, about 6% of patients receiving 
this form of prophylaxis will experience heparin-induced 
thrombocytopenia [12].
Low molecular weight heparins (LMWH) 
The most commonly used agent in thromboprophylaxis 
in gynecology is LMWH. Advantages of LMWH over UFH 
include greater bioavailability and once-daily dosing. The 
most common side effects are bleeding, allergic reactions 
and injection side reactions. Moreover, heparin induced 
thrombocytopenia is very rarely observed with LMWH [12]. 
However, renal function should be considered when select-
ing and dosing these agents, because they are excreted 
by kidneys. A Cochrane review of randomized, controlled 
trials in gynecologic patients undergoing major surgery 
and a systematic analysis of gynecologic oncology patients 
found LMW heparin and low-dose unfractionated heparin 
equally useful in preventing VTE [12].
Non-vitamin K antagonist oral anticoagulants 
(NOACs)
These agents include inhibitors of factor IIa (dabiga-
tran) and factor Xa (rivaroxaban, apixaban and edoxaban). 
An advantage to their use is that they do not require rou-
tine laboratory monitoring and they would be more con-
venient than LMWH which requires daily subcutaneous 
Table 1. Caprini risk model (modified, based on [11]) 
Each risk factor 
represents 1 point
Age 41–60 years
Swollen legs (current)
Varicose veins
Obesity (BMI > 25 kg/m2)
Minor surgery planned
Medical patient currently at bed rest
History of prior major surgery (< 1 month)
Serious lung disease including pneumonia 
(< 1 month)
Oral contraceptives or hormone 
replacement therapy
Pregnancy or postpartum (< 1 month)
History of unexplained stillborn infant, 
recurrent spontaneous abortion (> 3), 
premature birth with hypoxemia or 
growth-restricted infant
Each risk factor 
represents 2 points
Age 61–74
Malignancy (present or previous)
Laparoscopic surgery (> 45 min)
Patient confined to bed (> 72 h)
Central venous access
Major surgery (> 45 min)
Each risk factor 
represents 3 points
Age 75 or older
History of DVT/PE
Positive factor V Leiden
Heparin-induced thrombocytopenia (HIT)
Positive Prothrombin 20210A
Positive lupus anticoagulant
Other congenital or acquired 
thrombophilia
Each risk factor 
represents 5 points
Stroke (< 1 month)
Multiple trauma (< 1 month)
BMI — body mass index; DVT — deep vein thrombosis; PE — pulmonary 
embolism
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administration. However, due to the lack of data confirming 
their effect on perioperative thromboprophylaxis, these 
drugs are not approved in patients requiring gynecologi-
cal surgery [12].
Evidence-based guidelines regarding VTE prophylaxis 
are available from ACCP and The American College of Ob-
stetrics and Gynecology (ACOG) [3]. All the above guidelines 
recommend that women with moderate risk of VTE should 
receive HNF 5000 units twice a day and women with a very 
high risk of VTE — HNF therapy every 8 h. The ACCP guide-
lines for gynecological surgery patients at high risk of major 
bleeding complications were shown in Table 3. Furthermore, 
in women undergoing gynecological surgery at moderate or 
high risk for VTE who are at high risk for major perioperative 
bleeding complications should be given mechanical prophy-
laxis, preferably with intermittent pneumatic compression 
(IPC). The ACCP guidelines recommend the use of low-dose 
aspirin, fondaparinux or mechanical prophylaxis, preferably 
with IPC before the surgery for women with contraindica-
tion to both LMWH and unfractionated heparin treatment. 
The Polish Gynecological Society has developed guidelines 
based on recommendations of the American College of 
Obstetricians and Gynecologists (Table  2) [8]. The Polish 
guidelines approved by various Polish societies presented 
by Zawilska et al are based on the 2012 ACCP guidelines 
which slightly differ from above [13].
When prescribing antithrombic therapy before the sur-
gery it should be also provided the potential risk of perio-
perative bleeding complications in women threated with 
antithrombotic therapy due to concomitant diseases such 
as atrial fibrillation. 
Evaluating the extent of the surgery, due to ACCP state-
ment, women undergoing minor surgical or non-invasive 
procedures do not need to interrupt their antithrombotic 
therapy. However, to minimize the risk for perioperative 
bleeding complications patients having major surgical or 
invasive procedures should have their antithrombic therapy 
be intermitted (Table 3). 
To minimize the risk of perioperative bleeding in women 
undergoing warfarin, the treatment should be stopped in 
5 days before the surgery. However, patients taking anti-
platelet agents should interrupt the treatment in 7–10 days 
before the surgery. 
In patients with increased risk for thromboembolism 
(TE) bridging therapy with heparin should be considered. 
After surgery, bridging therapy increases hemorrhagic in-
cidents. The risk of perioperative bleeding depends on the 
anticoagulant dose and proximity to surgery with higher risk 
if the treatment starts closer to surgery. It has been reported 
that low-dose LMWH or UFH effectively prevent postopera-
tive VTE, whereas, there is no evidence that this treatment is 
efficient in acute TE prophylaxis [12]. Furthermore, in women 
with a mechanical heart valve, atrial fibrillation or VTE at 
high risk for thromboembolism, the ACCP experts suggest 
bridging anticoagulation therapy (Table 4).
In resuming antithrombotic therapy, it should be em-
phasized that the different time period is needed to achieve 
Table 2. Risk classification and recommended thromboprophylaxis (based on [17])
Level of VTE risk Definition Suggested thromboprophylaxis
Low Minor surgery (less than 30 min) or noncomplex laparoscopic surgery in patients with no additional risk factors Early, frequent ambulation
Moderate
Minor or laparoscopic surgery in patients with additional risk 
factors; major gynecologic surgery for benign disease and no 
additional risk factors
LMWH or low-dose UFH,
5,000 units twice a day, or IPC or GCS
High Major surgery in patients with additional risk factors; major surgery in patients with malignancy
LMWH or low-dose UFH
5,000 units three times a day, or IPC
Alternative considerations include a combination  
of low-dose UFH or LMWH plus mechanical prophylaxis 
with GCS or IPC
Very high Major surgery in patients older than 60 years with cancer, a prior venous thromboembolism, or both
5,000 units three times a day, plus IPC or GCP
Consider continuing LMWH prophylaxis for up to 4 weeks 
after discharge
LMWH — low molecular weight heparins; UFH — unfractionated heparin; IPC — intermittent pneumatic compression; GCS — graduated compression stockings
Table 3. Dosage of bridging anticoagulation in VTE prevention in 
gynecological patients (modified, based on [11])
Estimated risk for 
thromboembolism Bridging anticoagulation
High 
“High-dose” (therapeutic-dose):
• enoxaparin 1 mg/kg BID or 1.5 mg/kg QD
• dalteparin 100 IU/kg BID or 200 IU/kg QD
• IV UFH to attain aPTT 1.5- to 2-times the 
control aPTT
Moderate “Intermediate-dose”:• eg, enoxaparin 40 mg BID
Low
“Low-dose” (prophylactic-dose):
• enoxaparin 30 mg BID or 40 mg QD
• dalteparin 5000 IU QD
• UFH 5000–7500 IU BID
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a therapeutic effect after warfarin (2–3 days), LMWH (3–5 h), 
ASA (minutes), clopidogrel (3–7 days). The ACCP guidelines 
suggest the VKA treatment should be resumed 12–24 hrs af-
ter surgery and when the adequate hemostasis is obtained.
The ACCP guidelines state that most thrombotic or 
bleeding complications occur within first two weeks after 
the surgery, therefore strict observation is needed in postop-
erative women to implement early diagnosis and treatment 
limiting complications. 
THROMBOPROPHYLAXIS IN 
GYNECOLOGICAL ONCOLOGY PATIENTS
Patients with cancer have up to 7-fold increase risk of VTE 
in comparison to the general population [14–16]. It has been 
reported that approximately 38% of gynecological oncol-
ogy patients will suffer from perioperative thromboembolic 
complications without VTE prophylaxis, and PE remains the 
leading cause of postoperative death among these patients 
[17, 18]. It is due to the fact that patients with active malig-
nancy have additional VTE risk factors such as the malignancy 
itself, advanced age, vascular compression by a pelvic mass, 
lengthy surgery, vascular injury, and treatment with chemo-
therapy, which increases thrombotic risk [19]. 
Among gynecological tumors, ovarian cancer is associ-
ated with 5–16.6% risk of VTE and it is one of the highest 
incidence rates of venous thrombosis [20]. The molecular 
basis for increased risk of VTE among theese patients is still 
unknown, however, elevated tissue factor and D-dimer levels 
are suggested to promote a hypercoagulable state [21]. The 
VTE risk factors have been divided into early and late depend-
ing on the time of thrombembolism onset in relation to the 
cancer diagnosis. Early thromboembolic events are related 
to surgery and chemotherapy, whereas later VTE incidences 
were linked to older age, prior history of DVT, FIGO stage 
IIC–IV, and presence of residual tumor after initial surgery [22]. 
Moreover, the risk of VTE depends also on the histological 
subtypes of carcinomas and for example, the clear cell tumor 
is associated with the highest VTE incidence of 11–27% [23].
Endometrial carcinoma is one of the most common 
gynecologic malignancies. The most prominent risk factors 
include metabolic syndrome with obesity, hypertension, in-
sulin resistance, diabetes, and dyslipidemia [24]. Recent data 
have shown that VTE in endometrial cancer is associated 
with tumor aggressiveness. Moreover, subclinical VTE was 
observed in relatively large subsets of endometrial cancer 
patients prior to surgical treatment and more than half of 
the cases were diagnosed at around the time of recurrence 
or progression of tumor [25]. So far the relationship between 
the histological type of uterine cancer and VTE in unclear 
[26]. However, Matsuo et al. indicated that uterine serous 
carcinoma (type 2 endometrial cancer) was the most com-
mon histologic subtype associated with VTE [23].
The frequency of VTE in patients with diagnosed cer-
vical cancer vary widely from 0–34% mostly because of 
heterogeneous patient populations in individual studies 
and methodological differences [24]. The most common 
type of cervical cancer is squamous-cell carcinoma, with 
adenocarcinoma being the second most common. Probably, 
mucin-producing tumours (what was proved in pancreatic 
tumours) are associated with a higher risk of VTE [26]. In the 
cervical cancer, disease stage is defined by the extent of 
tumour spread to the parametria or pelvic side wall. There-
fore, the tumor’s proximity to the pelvic veins may result 
in venous compression and stasis, which are considered 
to increase the risk of VTE. It was reported that patients 
with advanced-stage cervical carcinoma have elevated con-
centrations of von Willebrand factor, fibrinopeptide A and 
D-dimer levels. Although, the clinical implication of this 
finding is unknown, the general cancer population show 
an increased risk of VTE in advanced-stage disease [27].
Treatment-related risk
In addition to the type and stage of cancer, oncological 
treatment also modulates the thrombotic potential. Fol-
lowing treatment: surgery, chemotherapy, antiangiogenic 
drugs, immunomodulatory agents, erythropoiesis-stimulat-
ing agents (ESAs), blood transfusions, and central venous 
catheters are all reported to be associated with an increased 
risk of VTE.
Major surgical procedures are associated with increased 
risk of venous thrombosis both in cancer and noncancer pa-
tients. In cancer patients, risk of three-months postopera-
tive venous thrombosis is reported to be twice as high as in 
noncancer patients [27]. The prevalence of DVT in untreated 
Table 4. ACCP recommendation antithrombotic prophylaxis (based on [11])
Risk of VTE Recommendation
Very low (< 0.5%, Caprini score, 0) No specific pharmacologic or mechanical prophylaxis other than early ambulation
Low (1.5%, Caprini score, 1–2 ) Mechanical prophylaxis, preferably with IPC
Moderate (~ 3.0%; Caprini score, 3–4) LMWH, low-dose UFH or mechanical prophylaxis, preferably with IPC
High (~6.0%; Caprini score, ≥ 5) Pharmacologic prophylaxis with LMWH or low-dose UFH. The mechanical prophylaxis with elastic stockings or IPC should be added to pharmacologic prophylaxis
LMWH — low molecular weight heparins; UFH — unfractionated heparin; IPC — intermittent pneumatic compression
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gynecologic oncology patients undergoing major surgery is 
approximately 40%, while the range of fatal PE is between 
0.2 and 0.9% [28]. In patient diagnosed with endometrial or 
cervical cancer minimally invasive surgery (MIS) is offered for 
definitive primary treatment. It was reported that this type of 
surgery is associated with less than 2% risk of VTE, which is defi-
nitely lower comparing to the open surgery. However, this low 
rate of VTE is underestimated due to the fact that patients used 
mechanical and/or anticoagulant thromboprophylaxis [27].
Chemotherapy leads to hypercoagulable state by se-
cretion of tumor lysis products and endothelial damage. 
Predictive biomarkers for VTE in ambulatory cancer patients 
have been proposed but, the utility of them in gynaecologi-
cal patients has not been well investigated [28]. Recent data 
from the Vienna prospective study show that elevated levels 
of P-selectin are predictive of thrombosis, and elevated 
D-dimer in addition to prothrombin 1.2 fragments (F1 + 2) 
are associated with increased risk of VTE in patients receiving 
chemotherapy [29]. Moreover, a prospective study reported 
2.7-fold increase in arterial thrombosis, and a 47-fold in-
crease in the mortality rate from VTE in patient undergoing 
chemotherapy compared to the general population [15].
Radiotherapy has also been reported as a probable risk 
factor for VTE, but its association with VTE has been poorly 
studied [30]. An essential component of curative radio-
therapy for cervical cancer is intracavitary brachytherapy. 
It involves instrumentation of the uterus under conscious 
sedation or general anaesthesia and immobilisation of the 
patient for hours to plan and deliver treatment. The avail-
able data suggest 1–1.2% incidence of VTE among women 
treated with brachytherapy for a variety of gynecologic 
tumors [30]. 
New anti-angiogenic drugs are entered to the treatment 
of various solid tumors [31]. However, it was reported that 
the addition of bevacizumab to chemotherapy regimens in 
ovarian cancer tratment is associated with a 12% incidences 
of VTE. Mechanisms for this side-effect are not well docu-
mented and, although bevacizumab has reported activity 
in cervical cancer it has not been widely studied in this 
setting [31].
Currently reported data show that supportive care 
agents, including erythropoietin and darbopoetin as an al-
ternative to red blood cell transfusions for correcting anae-
mia, appear to increase the risk of VTE and mortality in 
cancer patients [32]. 
Thrombophylaxis
Patients with active cancer disease develop thrombotic 
complications spontaneously, without any other risk fac-
tors. A history of VTE puts patients with cancer at a high risk 
of recurrence, that is why the systematic use of mechani-
cal or pharmacological prophylaxis should be considered. 
Despite of using thromboprophylaxis, some patients still 
develop VTE after discharge from the hospital. This phe-
nomenon is associated with the fact that VTE prophylaxis 
is given to most cancer patients only during hospitalization 
and the treatment is interrupted after discharge due to the 
risk of bleeding which is more common in cancer patients 
[17]. Although warfarin remains the mainstay of anticoagu-
lant therapy for VTE treatment, LMWH has been studied 
extensively and has been adopted as the anticoagulant 
of choice in the oncology setting [17]. The non vitamin 
K oral anticoagulants, i.e. direct thrombin inhibitors and 
factor-Xa inhibitors, are gaining acceptance as alternative 
oral anticoagulants to warfarin, they have not yet been suf-
ficiently studied to be recommended for the treatment or 
prophylaxis of thrombosis in patients with cancer [13]. It has 
been reported that in oncological patients at higher risk of 
perioperative bleeding graduated compression stockings 
and sequential compression devices should be given.
The 2012 ACCP guidelines suggest extended-dura-
tion pharmacologic prophylaxis (4 weeks) with LMWH for 
high-VTE-risk women undergoing gynecological surgery for 
cancer who are not otherwise at high risk for major bleeding 
complications [15]. However, ACCP states that further clinical 
trials are required to elaborate antithrombotic prophylaxis in 
gynecological oncology patients. The Polish Gynecological 
Society suggests to proceed these patients like in women 
with a very high risk of VTE (Table 2).
It has been reported that open gynecologic surgeries 
should be supported by the use of VTE prophylaxis. Despite 
the fact that the necessity of thromboprophylaxis in MIS is 
unclear recommendation stated by various medical organiza-
tions including ACOG for patients undergoing laparoscopy 
are the same as for women undergoing laparotomy. To our 
knowledge, among large societies, the ACCP is the only one 
that recommends against routine thromboprophylaxis for gy-
necology patients undergoing MIS, unless additional VTE risk 
factors, such as cancer are present. At our site, we have differ-
ent procedures according to the duration of hospitalization. 
In women prepared in the early recovery after surgery (ERAS) 
protocol and undergoing laparoscopic gynecologic oncology 
procedures we practice the same-day discharge after admis-
sion and they do not receive any form of VTE prophylaxis. On 
the other hand, women with current malignancy, which we 
expect to extend the stay in hospital we follow according the 
Polish Gynecological Society recommendation.
PROPHYLAXIS IN WOMEN UNDERGOING 
ASSISTED REPRODUCTIVE TECHNIQUES (ART)
Assisted reproduction appears to be associated with 
an increased risk of venous thromboembolism (OR: 4.3, 95% 
CI: 2.0–9.4) [33]. The mechanism behind the increased fre-
quency of VTE associated with ART remains unknown [33]. 
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Increased estrogen level may induce a procoagulant effect 
by increasing levels of von Willenbrand factor, factor VIII, fac-
tor V, and fibrinogen, together with decreased levels of the 
anticoagulants protein S and antithrombin [34]. However, the 
clinical relevance of these changes is unclear because most 
variables remain within the normal range [19]. It has been 
suggested that women with failure of assisted reproduction 
are more often positive for the factor V Leiden mutation and 
antiphospholipid antibodies [34]. However, these results were 
not confirmed in a meta-analysis of cohort studies [33]. 
The most serious complication of induction of ovulation 
used in ART is ovarian hyperstimulation syndrome (OHSS). 
The frequency and severity of OHSS depend on the clinical 
condition and the etiology in which ovulation is needed. 
The incidence and severity of OHSS vary with the different 
clinical conditions in which ovulation is induced and the 
type of the protocol which is used for ovarian stimulation. 
In women with anovulatory cycles the frequency of mild 
OHSS is 5–10%. However, 2–4% women treated by the ART 
suffers moderate OHSS and 0.1–0.5% — severe OHSS [35]. 
The vascular permeability is associated with the release 
of ovary vasoactive substances, such as vascular endothelial 
growth factor (VEGF), angiotensine, histamine, insulin-like 
growth factor 1 (IGF-1), epidermal growth factor (EGF), inter-
leukins. It results in fluid translocation out of the blood vessels 
and it leads to to hypovolemia and hemostasis disorders [33]. 
Low-dose ASA and/or prophylactic doses of LMWH are 
prescribed to women approaching ART. ASA treatment 
is thought to have positive effects both on placental cir-
culation, which leads to better implantation with higher 
pregnancy rate and on enhancing ovarian response to 
stimulation [33]. In turn, heparin is considered to improve 
implantation rates by both reducing the risk of implantation 
site microthrombosis and improving endometrial receptiv-
ity with decidualization of endometrial stromal cells, as well 
as trophoblast adhesion, and invasiveness [22]. However, 
available clinical data are inconsistent [35].
The ACCP guidelines do not recommend any thrombo-
prophylaxis for women undergoing assisted reproduction. 
However, women with developed OHSS should receive pro-
phylactic LMWH for 3 months after recovery regardless the 
success of ART. From our experience, we do not use routine 
thromboprophylaxis due to the risk of bleeding during ovar-
ian puncture in the course of the in vitro procedure. 
CONCLUSIONS
Prophylaxis in gynecological patients and women un-
dergoing assisted reproductive techniques should be cho-
sen individually for the patient, taking into account the 
possible risk factors for VTE and perioperative bleeding 
complications. Too small dose and inadequate treatment 
period increases the risk of developing the disease in the 
most dangerous complications — pulmonary embolism. 
Due to the possibility of bleeding complications enhanced 
surveillance and monitoring therapy especially after surgery 
is needed. However, prevention of venous thromboembo-
lism in cancer is an important challenge, because patients 
experiencing a thrombotic episode have a poor outcome 
with greater probability of death.
The decision for duration of thromboprophylaxis should 
be taken by balancing the risk of VTE and risk of bleeding. 
Factors that should be considered for making the decision are 
the incidence and burden of the VTE. Standardized and widely 
implemented approach to thromboprophylaxis in each gy-
necology center is needed to optimize clinical outcomes.
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